Search results
Combination Targeted Treatment Produces Lasting Remissions in People with Resistant Aggressive B-...
Sierra Sun Times· 3 days agoCombination therapy developed by NIH researchers demonstrates the power of precision medicine. June...
Researchers uncover mechanism that fuels growth of aggressive B-cell lymphoma
Science Daily· 6 days agoThe KLHL6 protein is part of a cellular system tasked with disposing of excess and unnecessary proteins. In many cancers, this system is disrupted, which advances malignant growth. The researchers ...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 4 days agoIn one study, Pfizer's Seagen-acquired drug, Adcetris, reduced the risk of death by 37% for patients...
...Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to...
Morningstar· 4 days agoALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure RatesFirst Prospective Trial to Incorporate the Foresight Diagnostics’s Investigational CLARITY™ Test to Identify Patients with LBCL Who
NIH Phase Ib/II DLBCL drug combo trial reports 34% complete response
Clinical Trials Arena via Yahoo Finance· 4 days agoA five drug combination drug therapy trial has shown substantial tumour shrinking in more than half...
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach...
Morningstar· 4 days agoPALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western
Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study
Zacks via Yahoo Finance· 7 days agoRoche's (RHHBY) Columvi significantly extends survival in patients with relapsed or refractory...
Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL
MedPage Today· 5 days agoHigh-rate of durable responses with ViPOR sparks talk of supplanting CAR-T in second line
Music therapy helps two-time cancer survivor throu | Newswise
Newswise· 3 days agoLEXINGTON, Ky. (June 21, 2024) – In 2018, Bobbi Jo Allen was exercising when she found a lump in her...
Glofitamab Regimen Improves Survival in DLBCL
MedPage Today· 4 days agoGranted accelerated approval last year, bispecific antibody passes its confirmatory test